for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AbbVie Inc

ABBV.N

Latest Trade

91.04USD

Change

0.34(+0.37%)

Volume

1,700,690

Today's Range

90.06

 - 

91.69

52 Week Range

62.55

 - 

97.86

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
90.70
Open
90.97
Volume
1,700,690
3M AVG Volume
280.78
Today's High
91.69
Today's Low
90.06
52 Week High
97.86
52 Week Low
62.55
Shares Out (MIL)
1,762.34
Market Cap (MIL)
159,844.40
Forward P/E
8.75
Dividend (Yield %)
5.20

Next Event

Q2 2020 Abbvie Inc Earnings Release

Latest Developments

More

Abbvie Submits Regulatory Applications To FDA & EMA For Rinvoq For Treatment Of Adults With Active Psoriatic Arthritis

FDA Approves Abbvie's Oriahnn To Treat Heavy Menstrual Bleeding Associated With Fibroids In Women

Ironwood, Abbvie Report MD-7246 Phase 2 Data In Patients With Abdominal Pain Associated With IBS-D

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry

Biotechnology & Drugs

Contact Info

1 N Waukegan Rd

NORTH CHICAGO, IL

60064-1802

United States

+1.847.9327900

https://www.abbvie.com/

Executive Leadership

Richard A. Gonzalez

Chairman of the Board, Chief Executive Officer

Michael E. Severino

President, Vice Chairman

Carlos Alban

Vice Chairman, Chief Commercial Officer

Laura J. Schumacher

Vice Chairman, External Affairs and Chief Legal Officer

Robert A. Michael

Chief Financial Officer, Senior Vice President

Key Stats

2.12 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

28.2K

2018

32.7K

2019

33.3K

2020(E)

45.7K
EPS (USD)

2017

5.600

2018

7.910

2019

8.940

2020(E)

10.285
Price To Earnings (TTM)
16.05
Price To Sales (TTM)
4.69
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
15.21
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
14.35
Return on Equity (TTM)
11.40

Latest News

Latest News

BRIEF-Abbvie Submits Regulatory Applications To FDA & EMA For Rinvoq For Treatment Of Adults With Active Psoriatic Arthritis

* ABBVIE SUBMITS REGULATORY APPLICATIONS TO FDA AND EMA FOR RINVOQ™ (UPADACITINIB) FOR THE TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS

BRIEF-Abbvie And Jacobio Announce Strategic Collaboration To Advance Shp2 Inhibitors

* ABBVIE AND JACOBIO ANNOUNCE STRATEGIC COLLABORATION TO ADVANCE SHP2 INHIBITORS

BRIEF-FDA Approves Abbvie's Oriahnn To Treat Heavy Menstrual Bleeding Associated With Fibroids In Women

* FDA APPROVES NEW OPTION TO TREAT HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH FIBROIDS IN WOMEN

FDA approves Abbvie's drug to control menstrual bleeding due to fibroids

The U.S. Food and Drug Administration on Friday approved Abbvie Inc's oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women.

FDA approves Abbvie's treatment to control menstrual bleeding

The U.S. Food and Drug Administration on Friday approved Abbvie Inc's oral treatment for managing heavy menstrual bleeding associated with fibroids in premenopausal women.

BRIEF-Ironwood, Abbvie Report MD-7246 Phase 2 Data In Patients With Abdominal Pain Associated With IBS-D

* IRONWOOD AND ABBVIE REPORT TOP-LINE PHASE II DATA FOR MD-7246 IN PATIENTS WITH ABDOMINAL PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D)

BRIEF-Synlogic Announces Termination Of Abbvie Collaboration Agreement

* SYNLOGIC ANNOUNCES TERMINATION OF ABBVIE COLLABORATION AGREEMENT

BRIEF-Abbvie Announces Final Results Of Exchange Offers For Allergan Notes

* ABBVIE ANNOUNCES FINAL RESULTS OF EXCHANGE OFFERS FOR ALLERGAN NOTES

BRIEF-Abbvie Says Stockholders Did Not Approve Proposal To Issue Annual Compensation Committee Report On Drug Pricing At Annual Meeting

* ABBVIE INC - STOCKHOLDERS DID NOT APPROVE A STOCKHOLDER PROPOSAL TO ISSUE AN ANNUAL COMPENSATION COMMITTEE REPORT ON DRUG PRICING AT ANNUAL MEETING

BRIEF-Abbvie Completes Acquisition Of Allergan

* ABBVIE COMPLETES TRANSFORMATIVE ACQUISITION OF ALLERGAN Source text for Eikon: Further company coverage:

BRIEF-Abbvie Says Borrowed $3.0 Bln Under Term Loan Credit Agreement

* ABBVIE INC - ON MAY 8 BORROWED $3.0 BILLION UNDER TERM LOAN CREDIT AGREEMENT TO FUND A PORTION OF CASH CONSIDERATION PAID TO ALLERGAN SHAREHOLDERS Source text: (https://bit.ly/2Wxozre) Further company coverage:

BRIEF-Abbvie Says Allergan CEO Brent Saunders Has Elected Not To Join Abbvie Board

* ABBVIE INC - ALLERGAN'S CURRENT CHAIRMAN AND CEO BRENT SAUNDERS HAS ELECTED NOT TO JOIN ABBVIE BOARD Source text: (https://bit.ly/2WrkrsY) Further company coverage:

AbbVie wins U.S. antitrust approval to buy Allergan

Drugmaker AbbVie Inc has won U.S. antitrust approval to buy Botox maker Allergan, a blockbuster $63 billion deal when it was announced last year, the companies said on Tuesday.

AbbVie wins U.S. antitrust approval to buy Allergan

Drugmaker AbbVie has won U.S. antitrust approval to buy Botox-maker Allergan, a blockbuster $63 billion deal when it was announced last year, the companies announced on Tuesday.

BRIEF-Abbvie Receives Health Canada Approval For The Combination Of Venclexta With Obinutuzumab

* ABBVIE RECEIVES HEALTH CANADA APPROVAL FOR THE COMBINATION OF VENCLEXTA® (VENETOCLAX) WITH OBINUTUZUMAB FOR PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA Source text for Eikon: Further company coverage:

AbbVie sees substantial hit to Botox from pandemic, lowers Humira growth forecast

AbbVie Inc <ABBV.N> on Friday said it expects the coronavirus outbreak to substantially limit sales of Botox and similar aesthetic products that the U.S. drugmaker is set to acquire through its buyout of Allergan Plc <AGN.N>.

BRIEF-Abbvie Says Saw Modest Impact To New Patient Starts For Some Drugs Due To COVID-19 Restrictions: Q1 Conf Call

* ABBVIE INC SAYS SAW MODEST IMPACT TO NEW PATIENT STARTS FOR SOME DRUGS DUE TO COVID-19 RESTRICTIONS IN Q1: CONF. CALL

BRIEF-Abbvie Reports Qtrly Adjusted Earnings Per Share $2.42

* ABBVIE QTRLY GAAP EARNINGS PER SHARE $2.02; QTRLY ADJUSTED EARNINGS PER SHARE $2.42

Abbvie quarterly sales beat as Humira shines; maintains forecast

AbbVie Inc stuck with its 2020 adjusted profit forecast on Friday after strong demand for its blockbuster rheumatoid arthritis drug, Humira, helped it beat analysts' estimates for quarterly sales.

BRIEF-Abbvie Announces Extension Of Expiration Date For Exchange Offers For Allergan Notes

* ABBVIE ANNOUNCES EXTENSION OF EXPIRATION DATE FOR EXCHANGE OFFERS FOR ALLERGAN NOTES

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up